Provention bio reports second quarter 2022 financial results and provides business update

-teplizumab biologics license application (bla) user fee goal date extended to november 17, 2022- -company completes $60.0 million private placement- red bank, n.j. , aug. 4, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended june 30, 2022, and provided a business update.
PRVB Ratings Summary
PRVB Quant Ranking